Evidence map›Paper›PMID 33851179›Full record

ArticlemedRxiv : the preprint server for health sciences2021

Signatures of COVID-19 severity and immune response in the respiratory tract microbiome.

Carter Merenstein, Guanxiang Liang, Samantha A Whiteside, Ana G Cobián-Güemes, Madeline S Merlino, Louis J Taylor, Abigail Glascock, Kyle Bittinger, Ceylan Tanes, Jevon Graham-Wooten and 11 more

Open access · greenAbstract readPreprint
In one paragraph

Article in medRxiv : the preprint server for health sciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 19 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

21 authors at 4 institutions in 1 country.

Carter MerensteinDepartment of Microbiology, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA 19104.
Guanxiang LiangDepartment of Microbiology, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA 19104.
Samantha A WhitesidePulmonary, Allergy and Critical Care Division; Department of Medicine; University of Pennsylvania Perelman School of Medicine; Philadelphia, PA 19104.
Ana G Cobián-GüemesDepartment of Microbiology, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA 19104.
Madeline S MerlinoDepartment of Microbiology, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA 19104.
Louis J TaylorDepartment of Microbiology, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA 19104.
Abigail GlascockDepartment of Microbiology, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA 19104.
Kyle BittingerDivision of Gastroenterology, Hepatology, and Nutrition, Children's Hospital of Philadelphia, Philadelphia, PA 19104.
Ceylan TanesDivision of Gastroenterology, Hepatology, and Nutrition, Children's Hospital of Philadelphia, Philadelphia, PA 19104.
Jevon Graham-WootenPulmonary, Allergy and Critical Care Division; Department of Medicine; University of Pennsylvania Perelman School of Medicine; Philadelphia, PA 19104.
Layla A KhatibPulmonary, Allergy and Critical Care Division; Department of Medicine; University of Pennsylvania Perelman School of Medicine; Philadelphia, PA 19104.
Ayannah S FitzgeraldPulmonary, Allergy and Critical Care Division; Department of Medicine; University of Pennsylvania Perelman School of Medicine; Philadelphia, PA 19104.
Shantan ReddyDepartment of Microbiology, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA 19104.
Amy E BaxterDepartment of Systems Pharmacology and Translational Therapeutics, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA 19104.
Josephine R GilesDepartment of Systems Pharmacology and Translational Therapeutics, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA 19104.
Derek A OldridgeInstitute for Immunology, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA 19104.
Nuala J MeyerPulmonary, Allergy and Critical Care Division; Department of Medicine; University of Pennsylvania Perelman School of Medicine; Philadelphia, PA 19104.
E John WherryDepartment of Systems Pharmacology and Translational Therapeutics, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA 19104.
John E McGinnissPulmonary, Allergy and Critical Care Division; Department of Medicine; University of Pennsylvania Perelman School of Medicine; Philadelphia, PA 19104.
Frederic D BushmanDepartment of Microbiology, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA 19104.
Ronald G CollmanPulmonary, Allergy and Critical Care Division; Department of Medicine; University of Pennsylvania Perelman School of Medicine; Philadelphia, PA 19104.
University of Pennsylvania · USPulmonary and Allergy Associates · USTranslational Therapeutics (United States) · USChildren's Hospital of Philadelphia · US

Funding

Virology CoreU19AI082630 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI RAYMOND T CHUNG, GEORG Michael LAUER · 2009 to 2026
$48.1M
IMMUNOBIOLOGY OF NORMAL AND NEOPLASTIC LYMPHOCYTEST32CA009140 · NCI · UNIVERSITY OF PENNSYLVANIA · PI Malay Haldar, WARREN S PEAR · 1985 to 2026
$16.1M
Institutional Clinical and Translational Science AwardKL2TR001879 · NCATS · UNIVERSITY OF PENNSYLVANIA · PI MEAGHER, EMMA ANNE · 2016 to 2025
$13.7M
The Lung DNA Virome in Health and DiseaseR33HL137063 · NHLBI · UNIVERSITY OF PENNSYLVANIA · PI BUSHMAN, FREDERIC D, COLLMAN, RONALD G · 2019 to 2021
$2.3M
Cellular and transcriptional control of exhausted CD8 T cells lineage dynamicsR01AI105343 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI WHERRY, E. JOHN · 2014 to 2017
$1.6M
Host-microbiome interactions after lung transplantation and chronic lung allograft dysfunctionK23HL158068 · NHLBI · UNIVERSITY OF PENNSYLVANIA · PI MCGINNISS, JOHN EVAN · 2021 to 2022
$387k
NCATS NIH HHS KL2 TR001879NCI NIH HHS T32 CA009140NHLBI NIH HHS K23 HL158068NHLBI NIH HHS L30 HL149040NHLBI NIH HHS R33 HL137063NIAID NIH HHS R01 AI105343NIAID NIH HHS U19 AI082630
6 · The paper itself

Abstract

Rationale: Viral infection of the respiratory tract can be associated with propagating effects on the airway microbiome, and microbiome dysbiosis may influence viral disease. Objective: To define the respiratory tract microbiome in COVID-19 and relationship disease severity, systemic immunologic features, and outcomes. Methods and Measurements: We examined 507 oropharyngeal, nasopharyngeal and endotracheal samples from 83 hospitalized COVID-19 patients, along with non-COVID patients and healthy controls. Bacterial communities were interrogated using 16S rRNA gene sequencing, commensal DNA viruses Main Results: COVID-19 patients had upper respiratory microbiome dysbiosis, and greater change over time than critically ill patients without COVID-19. Diversity at the first time point correlated inversely with disease severity during hospitalization, and microbiome composition was associated with L/N ratios and PBMC profiles in blood. Intubated patients showed patient-specific and dynamic lung microbiome communities, with prominence of Conclusions: The respiratory tract microbiome and commensal virome are disturbed in COVID-19, correlate with systemic immune parameters, and early microbiome features discriminate disease severity. Future studies should address clinical consequences of airway dysbiosis in COVID-19, possible use as biomarkers, and role of bacterial and viral taxa identified here in COVID-19 pathogenesis.

Indexed as

16S rRNA gene sequencingAnelloviruscoronavirusRedondovirusrespiratory microbiomeSARS-CoV-2

Identifiers

PMID33851179
PMCPMC8043476
OpenAlexW3152017481

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.